Highlights Dyadic International, Inc.

Equities

DYAI

US26745T1016

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-29 pm EDT			5-day change	1st Jan Change
1.39 ^USD	-6.70%		-9.14%	-13.66%

Mar. 28	Transcript : Dyadic International, Inc., 2023 Earnings Call, Mar 28, 2024
Mar. 28	Dyadic International, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Dyadic International, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Dyadic Advances Collaboration with Israel Institute for Biological Research Targeting Bio-Threats and Emerging Disease Solutions	Feb. 21	CI
Dyadic International Partners With Maravai LifeSciences' Cygnus Technologies Unit on HCP Assay	Feb. 13	MT
Dyadic International Inc. and Cygnus Technologies Announce Partnership to Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing	Feb. 13	CI
Dyadic International, Inc. Announces Top-Line Results from Its Successful Phase 1 Clinical Trial for A First-In-Human Filamentous Fungal-Based Vaccine Candidate	Nov. 29	CI
Dyadic International Says C1 Platform Chosen for Vaccine Production in Africa	Nov. 20	MT
Dyadic International, Inc. Announces its C1 Platform to Be Use to Produce Vaccines for Humans and Animals in Africa	Nov. 20	CI
Dyadic International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Janssen Biotech, Inc. Terminates Research, License, and Collaboration Agreement with Dyadic International, Inc	23-10-06	CI
Dyadic International, Inc. Enters into Research Collaboration Agreement with Voltron Therapeutics, Inc	23-10-05	CI
Dyadic International, Inc. and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells	23-09-26	CI
Dyadic International, Inc. Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus?	23-09-19	CI
Dyadic International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Earnings Flash (DYAI) DYADIC INTERNATIONAL Posts Q2 Revenue $837,159, vs. Street Est of $1.3M	23-08-09	MT
Dyadic Announces Positive Results from Third Party Analytical Testing of Animal-Free Recombinant Serum Albumin	23-08-07	CI
Dyadic International, Inc Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate	23-07-24	CI
Dyadic International, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Earnings Flash (DYAI) DYADIC INTERNATIONAL Posts Q1 Revenue $978,052	23-05-10	MT
Dyadic International, Inc. Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus™	23-05-08	CI
Dyadic International Says it has Received a Notice of Allowance for a Patent Application for Seasonal, Pandemic Flu Vaccines	23-04-18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Dyadic International, Inc.

Equities

DYAI

US26745T1016

Highlights

Filters